Bullish Moving Averages
16
Bearish Moving Averages
0
Back Stocks profile
Stock analysis tool for investors
Open an Account with Bigul in 5 minutes
Performance
Today’s low
115.80Today’s High
127.4052W low
59.6052W High
129.00Open Price
119.50Prev. Close
91.6500Volume
3310072.00Value
421802474.96Fundamentals
Market Cap
2778.90
Price to Earnings
-26.40
Price to Book Value
10.30
Dividend Yield
0.00
PE to Growth
-2.40
Op Revenue TTM
11.69
Net Profit TTM
-105.08
Cash From Operating Activity
-82.62
Return on Equity %
-38.91
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
05 Jul, 2024
54.7
Week
58
Month
60.7
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
123.56
PIVOT
First Resistance
131.30
Second Resistance
135.16
Third Resistance
142.90
First Support
119.70
Second Support
111.96
Third Support
108.10
Relative Strength Index
79.46
Money Flow Index
87.8
MACD
4.39
MACD Signal
1.8
Average True Range
5.56
Average Directional Index
24.41
Rate of Change (21)
45.97
Rate of Change (125)
38.21
Commodity Channel Index
286.9
Williams %R
BETA
1 Month
0.26
3 Month
0.82
1 Year
0.92
3 Year
0.37
PRICE CHANGE ANALYSIS
↑ 23.6%
1 Week
Low
High
103.32
127.43
↑ 45.97%
1 Month
Low
High
82.95
127.43
↑ 19.04%
3 Months
Low
High
82.95
127.43
↑ 36.95%
6 Months
Low
High
82.95
129
↑ 109.93%
1 Year
Low
High
59.6
129
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 6.67 | 8.52 | 8.20 | 9.44 | 8.21 | 5.21 | 4.59 | 3.98 | 4.34 | 4.57 | 1.69 | |
| Operating Expenses Qtr | 9.25 | 11.65 | 11.13 | 10.59 | 8.74 | 10.11 | 11.84 | 10.60 | 11.69 | 11.44 | 11.49 | |
| Operating Profit Qtr | -6.87 | -9.20 | -8.07 | -6.79 | -6.13 | -7.10 | -7.45 | -7.07 | -7.47 | -7.01 | -10.30 | |
| EBIDT Qtr Cr | -2.59 | -3.13 | 4.52 | -1.15 | -0.52 | -4.90 | -7.24 | -0.63 | -7.35 | -6.87 | -9.80 | |
| Depreciation Qtr | 1.51 | 1.60 | 1.73 | 1.66 | 1.67 | 1.67 | 1.62 | 1.58 | 1.10 | 1.22 | 1.03 | |
| Net Profit Qtr | -3.12 | -4.77 | 2.75 | -2.87 | -2.25 | -6.63 | -8.93 | -2.31 | -8.55 | -8.22 | -10.98 | |
| Basic EPS Qtr | -0.14 | -0.22 | 0.13 | -0.13 | -0.05 | -0.35 | -0.61 | -0.16 | -0.67 | -0.65 | -0.86 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 32.82 | 21.99 | 17.16 | 21.23 | 28.45 | |
| Operating Expenses Annual Cr | 42.63 | 41.28 | 48.49 | 44.03 | 49.68 | |
| Operating Profit Annual | -30.94 | -27.74 | -36.64 | -30.55 | -35.26 | |
| Operating Profit Margin Annual % | -94.25 | -126.18 | -213.52 | -143.87 | -123.94 | |
| Total Expenses Annual Cr | 49.29 | 48.12 | 53.41 | 49.19 | 54.39 | |
| EBIDT Annual Cr | -9.81 | -19.29 | -31.33 | -22.79 | -21.23 | |
| EBIDT Annual margin % | -29.88 | -87.75 | -182.53 | -107.35 | -74.61 | |
| Depreciation | 6.50 | 6.54 | 4.39 | 4.35 | 4.17 | |
| PAT Before ExtraOrdinary Items Annual Cr | -8.01 | -20.13 | -36.25 | -22.63 | -13.75 | |
| Net Profit Annual | -8.01 | -20.13 | -36.25 | -22.63 | -13.75 | |
| Basic EPS Annual | -0.37 | -1.13 | -2.84 | -1.78 | -1.08 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 845.38 | 853.44 | 475.98 | 401.65 | 387.67 | |
| Minority Interest Liability Annual Cr | - | - | - | - | - | |
| Total Non Current Liabilities Annual Cr | 1.35 | 2.46 | 3.57 | 4.50 | 12.07 | |
| Total Current Liabilities Annual Cr | 4.76 | 4.54 | 6.80 | 9.23 | 10.01 | |
| Total Capital Plus Liabilities Annual Cr | 851.48 | 860.44 | 486.35 | 415.39 | 409.76 | |
| Fixed Assets Annual | 27.69 | 37.21 | 41.12 | 25.74 | 24.69 | |
| Total Non Current Assets Annual | 605.34 | 619.18 | 422.13 | 320.76 | 357.76 | |
| Total Current Assets Annual | 246.14 | 241.26 | 64.22 | 94.62 | 52.00 | |
| Total Assets Annual | 851.48 | 860.44 | 486.35 | 415.39 | 409.76 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 0.00 | 0.00 | 0.00 | 0.00 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 12.29 | -10.09 | -36.62 | -36.68 | -103.43 | |
| Cash from Investing Activity Annual | -33.53 | -361.66 | -107.46 | 2.41 | 101.37 | |
| Cash from Financing Annual Activity | -1.05 | 395.54 | 145.69 | 34.86 | 2.75 | |
| Net Cash Flow Annual | - | 23.79 | 1.61 | 0.58 | 0.69 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 38.77 | 39.14 | 32.74 | 31.56 | 30.46 | |
| ROE Annual % | -0.94 | -2.35 | -7.61 | -5.63 | -3.54 | |
| ROCE Annual % | -1.92 | -3.01 | -7.44 | -6.68 | -6.35 | |
| Total Debt to Total Equity Annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EBDIT Annual Margin % | -83.86 | -142.51 | -264.47 | -169.11 | -147.26 |
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 6.67 | 8.52 | 8.20 | 9.44 | 8.21 | 5.21 | 4.59 | 3.98 | 4.34 | 4.57 | 1.69 | |
| Operating Expenses Qtr | 32.67 | 48.64 | 26.57 | 31.81 | 34.13 | 54.59 | 26.09 | 24.62 | 23.94 | 36.91 | 28.80 | |
| Operating Profit Qtr | -30.29 | -46.19 | -23.51 | -28.01 | -31.52 | -51.59 | -21.70 | -21.08 | -19.72 | -32.48 | -27.62 | |
| EBIDT Qtr Cr | -26.00 | -40.13 | -10.91 | -22.37 | -25.92 | -49.38 | -21.49 | -14.64 | -19.60 | -32.34 | -27.11 | |
| Depreciation Qtr | 1.51 | 1.60 | 1.73 | 1.66 | 1.67 | 1.67 | 1.62 | 1.58 | 1.10 | 1.22 | 1.03 | |
| Net Profit Qtr | -26.54 | -41.76 | -12.68 | -24.09 | -27.64 | -51.12 | -23.18 | -16.33 | -20.80 | -33.69 | -28.30 | |
| Basic EPS Qtr | -1.22 | -1.92 | -0.58 | -1.10 | -1.17 | -2.90 | -1.59 | -1.12 | -1.63 | -2.65 | -2.22 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 32.82 | 21.99 | 17.16 | 21.23 | 28.45 | |
| Operating Expenses Annual Cr | 139.70 | 139.42 | 134.23 | 93.54 | 130.13 | |
| Operating Profit Annual | -128.00 | -125.88 | -122.39 | -80.07 | -115.72 | |
| Operating Profit Margin Annual % | -389.99 | -572.51 | -713.16 | -377.10 | -406.72 | |
| Total Expenses Annual Cr | 146.36 | 146.26 | 139.16 | 98.71 | 134.85 | |
| EBIDT Annual Cr | -106.87 | -117.44 | -117.07 | -72.31 | -101.68 | |
| EBIDT Annual margin % | -325.61 | -534.08 | -682.18 | -340.58 | -357.39 | |
| Depreciation | 6.50 | 6.54 | 4.39 | 4.35 | 4.17 | |
| PAT Before ExtraOrdinary Items Annual Cr | -105.08 | -118.27 | -122.00 | -72.15 | -94.22 | |
| Net Profit Annual | -105.08 | -118.27 | -122.00 | -72.15 | -94.22 | |
| Basic EPS Annual | -4.82 | -6.63 | -9.57 | -5.67 | -7.40 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 270.04 | 375.32 | 96.15 | 108.01 | 143.35 | |
| Minority Interest Liability Annual Cr | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non Current Liabilities Annual Cr | 1.35 | 2.46 | 3.57 | 4.50 | 12.07 | |
| Total Current Liabilities Annual Cr | 13.52 | 11.13 | 8.31 | 15.91 | 26.51 | |
| Total Capital Plus Liabilities Annual Cr | 284.90 | 388.91 | 108.03 | 128.42 | 181.93 | |
| Fixed Assets Annual | 27.69 | 37.21 | 41.12 | 25.74 | 24.69 | |
| Total Non Current Assets Annual | 28.23 | 137.32 | 41.44 | 25.74 | 115.95 | |
| Total Current Assets Annual | 256.67 | 251.59 | 66.59 | 102.68 | 65.99 | |
| Total Assets Annual | 284.90 | 388.91 | 108.03 | 128.42 | 181.93 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 0.00 | 0.00 | 0.00 | 0.00 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | -82.62 | -103.15 | -127.54 | -96.02 | -193.85 | |
| Cash from Investing Activity Annual | 61.59 | -260.65 | -22.23 | 55.84 | 205.55 | |
| Cash from Financing Annual Activity | -1.05 | 395.54 | 145.69 | 34.86 | 2.74 | |
| Net Cash Flow Annual | - | 31.75 | -4.07 | -5.33 | 14.45 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 12.38 | 17.21 | 6.61 | 8.49 | 11.26 | |
| ROE Annual % | -38.91 | -31.51 | -126.88 | -66.80 | -65.72 | |
| ROCE Annual % | -41.77 | -32.81 | -121.80 | -68.13 | -68.10 | |
| Total Debt to Total Equity Annual | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 | |
| EBDIT Annual Margin % | -914.01 | -867.37 | -988.42 | -536.50 | -705.39 |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED (InitscapacityassoletrusteeofJastiFamilyTrust) | 69.56 | 74537759 | 0 | 11.93 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| QUANT MUTUAL FUND - QUANT BUSINESS CYCLE FUND | 1.05 | 74537762 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| HUF | 0.98 | 74537768 |
| RAMBABU CHIRUMAMILLA | 1.38 | 74537774 |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| Feb 14, 2019 | 1.5 | INTERIM | Feb 15, 2019 | Equity Share |
| Feb 06, 2018 | 1.5 | INTERIM | Feb 07, 2018 | Equity Share |
| Feb 08, 2017 | 1 | INTERIM | Feb 09, 2017 | Equity Share |
| Mar 14, 2016 | 1 | SPECIAL | Mar 15, 2016 | Equity Share |
| Mar 14, 2016 | 1 | INTERIM | Mar 15, 2016 | Equity Share |
| Jul 23, 2015 | 0.6 | FINAL | - | Equity Share |
| Jul 24, 2014 | 2 | SPECIAL | - | Equity Share |
| Jul 24, 2014 | 0.5 | FINAL | - | Equity Share |
| Aug 01, 2013 | 0.3 | FINAL | - | Equity Share |
| Sep 17, 2012 | 0.3 | FINAL | - | Equity Share |
| Aug 01, 2011 | 0.25 | FINAL | - | Equity Share |
| Jul 19, 2010 | 0.25 | FINAL | - | Equity Share |
| Sep 14, 2009 | 0.25 | FINAL | - | Equity Share |
| Sep 11, 2008 | 0.25 | FINAL | - | Equity Share |
| Sep 21, 2007 | 0.25 | FINAL | - | Equity Share |
| Sep 25, 2006 | 1 | FINAL | - | Equity Share |
| Sep 05, 2005 | 1 | FINAL | - | Equity Share |
| Sep 10, 2004 | 1 | FINAL | - | Equity Share |
| Sep 12, 2003 | 4.5 | FINAL | - | Equity Share |
| Sep 05, 2002 | 4 | FINAL | - | Equity Share |
| Sep 28, 2001 | - | FINAL | - | Equity Share |
| Ex-Date | Split Ratio | Record Date |
|---|---|---|
| Mar 23, 2007 | 2:1 | 2007-04-02 |
| Jan 15, 2004 | 10:2 | 2004-01-23 |
| Ex-Date | Purpose | Notes |
|---|---|---|
| May 06, 2024 | Audited Results | - |
| Jan 30, 2024 | Quarterly Results | - |
| Nov 04, 2023 | Quarterly Results | - |
| Aug 08, 2023 | Quarterly Results | - |
| May 09, 2023 | Audited Results | - |
| Feb 02, 2023 | Quarterly Results | - |
| Nov 10, 2022 | Quarterly Results | - |
| Oct 12, 2022 | Right issue of equity shares | - |
| Jul 26, 2022 | Quarterly Results | - |
| Jun 24, 2022 | Rights issue | Inter alia, to consider matters related to raising of funds through issue of equity shares of the Company on rights basis to the existing equity shareholders of the Company. |
| May 07, 2022 | Audited Results | - |
| Jan 31, 2022 | Quarterly Results | - |
| Oct 25, 2021 | Quarterly Results | - |
| Aug 09, 2021 | Quarterly Results | - |
| May 04, 2021 | Audited Results | - |
| Jan 28, 2021 | Quarterly Results | - |
| Oct 27, 2020 | Quarterly Results | - |
| Aug 11, 2020 | Quarterly Results & ESOP | - |
| Jun 05, 2020 | Audited Results | - |
| Feb 13, 2020 | Quarterly Results | - |
| Nov 14, 2019 | Quarterly Results | - |
| Aug 14, 2019 | Quarterly Results | - |
| May 25, 2019 | Audited Results | - |
| Mar 09, 2019 | Others | To consider and approve the investments in new overseas subsidiary and other matters, if any. |
| Feb 05, 2019 | Quarterly Results & Interim Dividend | - |
| Nov 14, 2018 | Quarterly Results | - |
| Aug 14, 2018 | Unaudited Financial Results | - |
| May 15, 2018 | Audited Results | - |
| Jan 30, 2018 | Quarterly Results & Interim Dividend | - |
| Nov 11, 2017 | Quarterly Results | - |
| Aug 14, 2017 | Quarterly Results | - |
| May 13, 2017 | Audited Results | - |
| Feb 01, 2017 | Quarterly Results & Interim Dividend | - |
| Nov 24, 2016 | Quarterly Results | - |
| Aug 10, 2016 | Quarterly Results | - |
| May 27, 2016 | Audited Results | - |
| Mar 05, 2016 | Interim Dividend | - |
| Feb 12, 2016 | Quarterly Results | - |
| Nov 10, 2015 | Quarterly Results | - |
| Aug 14, 2015 | Quarterly Results | Interalia, has authorized to create an overseas subsidiary with an initial investment of US$ 25 Mn for clinical development and commercialization of Suven pipeline and in-licensed molecules. |
| May 26, 2015 | Audited Results & Dividend | - |
| Feb 10, 2015 | Quarterly Results | Mr. P. Subba Rao, the GM (Finance & Costing) has been appointed as Chief Financial Officer (CFO) of the Company by the Board. |
| Nov 14, 2014 | Quarterly Results | - |
| Sep 22, 2014 | Alteration of AoA of the Company | 1. To consider alteration of Articles of Association of the Company. 2. To consider fund raising programmes through various means. |
| Aug 12, 2014 | Quarterly Results | - |
| May 22, 2014 | Audited Results & Dividend | - |
| Feb 04, 2014 | Quarterly Results | - |
| Nov 11, 2013 | Quarterly Results | - |
| Aug 13, 2013 | Quarterly Results | - |
| May 14, 2013 | Audited Results & Dividend | - |
| Feb 12, 2013 | Quarterly Results | - |
| Nov 14, 2012 | Quarterly Results | - |
| Aug 14, 2012 | Audited, Quarterly Results & Dividend | For year ended 31-03-2012 & for quarter ended 30-6-2012. |
| May 04, 2012 | Quarterly Results | - |
| Jan 31, 2012 | Quarterly Results & Others | The Board has given its consent for the Amalgamation of the said Wholly owned Subsidiary - Suven Nishtaa Pharma Private Limited with the holding Company - Suven Life Sciences Limited. |
| Nov 01, 2011 | Quarterly Results | - |
| Aug 13, 2011 | Quarterly Results | - |
| May 30, 2011 | Audited Results & Dividend | - |
| Jan 31, 2011 | Quarterly Results | - |
| Oct 27, 2010 | Quarterly Results | - |
| Jul 27, 2010 | Quarterly Results | - |
| Apr 30, 2010 | Audited Results & Dividend | - |
| Jan 27, 2010 | Quarterly Results | - |
| Oct 31, 2009 | Quarterly Results | - |
| Sep 22, 2009 | To approve the Cost Accounts | inter alia, to consider and approve Cost Accounts of the Company for the year 2008-09. |
| Jul 28, 2009 | Audited, Qtr. Results, Dividend & Others | To raise funds to the tune of 50 Million USD or its equivalent of any other Foreign/ Indian currencies through issue of Equity Shares / GDRs / ADRs / FCCBs and /or such other securities. |
| Apr 29, 2009 | Quarterly Results | - |
| Jan 19, 2009 | Quarterly Results | - |
| Oct 31, 2008 | Quarterly Results | - |
| Sep 18, 2008 | To consider & approve Cost Accounts | To consider and approve Cost Accounts of the Company for the year 2007-2008. |
| Jul 25, 2008 | Audited, Quarterly Results & Dividend | To announce Book Closure for the purpose of AGM and distribution of Dividend. |
| Apr 26, 2008 | Quarterly Results | - |
| Jan 28, 2008 | Quarterly Results | - |
| Oct 30, 2007 | Quarterly Results | - |
| Sep 27, 2007 | To approve the Cost Accounts | To consider and approve the Cost Accounts of the Company for the year 2006-2007. |
| Jul 31, 2007 | Audited Results, Dividend & Qtr Results | - |
| Apr 26, 2007 | Quarterly Results | - |
| Jan 29, 2007 | Quarterly, Bonus Issue & Stock Split | - |
| Dec 06, 2006 | To consider and issue and allot | 37,25,000 equity shares of Rs 2/- each to the shareholders of Asian Clinical Trials Ltd (Transferor Company) |
| Oct 30, 2006 | Quarterly Results | - |
| Sep 30, 2006 | To consider the Cost Accounts | To consider the Cost Accounts of the Company for the year 2005-06. |
| Jul 31, 2006 | Accounts, Dividend & Qtr. Results | for the year ended 31st March, 2006. |
| Apr 29, 2006 | Quarterly Results | - |
| Mar 06, 2006 | Scheme of Arrangement | To approve the draft Scheme of merger of Asian Clinical Trials Ltd with the Company. (Revised) |
| Jan 28, 2006 | Quarterly Results | - |
| Oct 29, 2005 | Quarterly Results | - |
| Jul 30, 2005 | Accounts, Dividend & Quarterly Results | - |
| Apr 28, 2005 | Quarterly Results | - |
| Jan 15, 2005 | Quarterly Results | - |
| Oct 28, 2004 | Quarterly Results | - |
| Sep 17, 2004 | General | - |
| Jul 30, 2004 | Accounts, Dividend & Quarterly Results | - |
| Apr 26, 2004 | Quarterly Results | - |
| Jan 31, 2004 | Quarterly Results | - |
| Jan 05, 2004 | Others | To consider & announce the record date for the purpose of of subdivision of Equity shares into Face value of Rs. 2/- each. |
| Dec 04, 2003 | Stock Split & Others | Merger of subsidiary - Suven Synthetics Ltd. into Suven Life Sciences Ltd. & Increase of investment limits of FII's |
| Oct 21, 2003 | Quarterly Results | - |
| Jul 31, 2003 | Quarterly Results, Dividend & Accounts | - |
| Apr 26, 2003 | Quarterly Results | - |
| Jan 30, 2003 | Quarterly Results | - |
| Oct 29, 2002 | Quarterly Results | - |
| Jul 29, 2002 | Accounts, Dividend & Quarterly Results | - |
| Apr 23, 2002 | Quarterly Results | - |
| Mar 09, 2002 | Interim Dividend | (Cancelled) |
| Jan 21, 2002 | Quarterly Results | (Revised) |
| Oct 31, 2001 | Quarterly Results | - |
| Jul 31, 2001 | Accounts, Dividend & Quarterly Results | - |
| Apr 30, 2001 | Quarterly Results & Preferential offer | Allotment of 4,00,000 equity shares on Preferential basis to M/s Boregaard Industries Ltd. Norway. |
| Jan 23, 2001 | Quarterly Results | - |
| Jan 06, 2001 | Others | To issue of equity shares and / or FCD together not exceeding 10,00,000 equity shares of Rs.10/- each of the company, at a price not less than the price calculated as per SEBI guidelines. |
| Oct 30, 2000 | Quarterly Results | - |
| Jul 26, 2000 | Quarterly Results | - |
| Apr 17, 2000 | Accounts & Dividend | - |
| Jan 31, 2000 | Quarterly Results | - |
| Oct 23, 1999 | Quarterly Results | - |
| Jul 19, 1999 | Quarterly Results | - |
| May 01, 1999 | Accounts | - |
| Jan 16, 1999 | Quarterly Results | - |
| Oct 30, 1998 | Quarterly Results | - |
| Jul 30, 1998 | Quarterly Results | - |
| Jun 23, 1998 | Accounts | - |
| Nov 27, 1997 | Half Yearly Results | - |
| Oct 25, 1997 | Accounts & Dividend | - |
| May 31, 1997 | Half Yearly Results | - |
| Ex-Date | Bonus Ratio | Record Date |
|---|---|---|
| Mar 23, 2007 | 1:1 | 2007-04-02 |
05 Jul 2024
SUVEN LIFE SCIENCES LTD. - 530239 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Enclosed copies of newspaper advertisement appeared regarding Notice of 35th AGM of the Company.
04 Jul 2024
SUVEN LIFE SCIENCES LTD. - 530239 - Business Responsibility and Sustainability Reporting (BRSR)
Enclosed the BRSR for FY 2023-24, forms part of Annual Report
04 Jul 2024
SUVEN LIFE SCIENCES LTD. - 530239 - Notice Of 35Th Annual General Meeting (AGM) Of The Company.
35th Annual General Meeting of the Company will be held on Friday, August 02, 2024 through VC/OAVM mode
04 Jul 2024
SUVEN LIFE SCIENCES LTD. - 530239 - Reg. 34 (1) Annual Report.
Annual Report FY 2023-24 including Notice of 35th Annual General Meeting (AGM) of the Company
29 Jun 2024
SUVEN LIFE SCIENCES LTD. - 530239 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Information regarding the 35th Annual General Meeting
28 Jun 2024
SUVEN LIFE SCIENCES LTD. - 530239 - Closure of Trading Window
Intimation of closure of trading window
28 May 2024
SUVEN LIFE SCIENCES LTD. - 530239 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudharani Jasti
24 May 2024
SUVEN LIFE SCIENCES LTD. - 530239 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance report for FY ended 31st March 2024
10 May 2024
SUVEN LIFE SCIENCES LTD. - 530239 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Enclosed herewith Monitoring Agency Report for quarter ended March 31, 2024 issued by CRISIL.
08 May 2024
SUVEN LIFE SCIENCES LTD. - 530239 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Audited Financial Results of the Company for the Quarter and Year ended March 31, 2024
